1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Xeno Transplants Corporation

Xeno Transplants Corporation

XENO
Xeno Transplants CorporationUS flagOther OTC
0.00
USD
- -
- -
4,036.00Market Cap
2005 Y
2006 Y
2007 Y
TTM
Revenue per Share
- -
- -
- -
- -
Basic EPS, GAAP
-0.01
-0.01
- -
-0.01
Free Cash Flow per Basic Share
-0.01
- -
-0.02
-0.01
Dividend per Share
- -
- -
- -
- -
Book Value per Share
- -
-0.01
-0.01
-0.02
Tangible Book Value per Share
0.01
- -
0.01
-0.02
Basic Weighted Avg Shares
6
9
33
40
Sales/Revenue/Turnover
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
-1
Effective Tax Rate (%)
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
Working Capital
- -
- -
- -
-1
LT Debt
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'08
Dec'08
Mar'08
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
40
40
40
Market Capitalization
26
19
4

Working Capital

FRC

•

in mil. unless spec.
Sep'08
Dec'08
Mar'08
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
1
1
Payables & Accruals
- -
- -
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-3,182.4%
Free Cash Flow
- -
- -
1,909.55%
Net Income, GAAP
- -
- -
174.74%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
- -
- -
- -
- -
- -
2007
- -
- -
- -
- -
- -
2008
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
- -
- -
- -
- -
-0.01
2007
- -
- -
- -
- -
- -
2008
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
- -
- -
- -
- -
- -
2007
- -
- -
- -
- -
- -
2008
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Elliot Lebowitz
Sector
Healthcare
Industry
Biotechnology
Address
143 Gardner Road Brookline MA United States of America 02445
IPO Date
Aug 1, 2006
Website
xenotransplants.com
Similar Companies
Virpax Pharmaceuticals, Inc. (VRPX)
Cyclacel Pharmaceuticals, Inc. (CYCCP)
UnicoCell Biomed Co., Ltd. (6794.TW)
RAPT Therapeutics, Inc. (RAPT)
Intec Pharma Ltd (NTEC)
LabTurbo Biotech Corporation (7725.TWO)
Business
Xeno Transplants Corporation (XENO) operates as a biotechnology research and development company focused on xenotransplantation, developing, manufacturing, distributing, and commercializing products and processes for cell, tissue, and organ transplants from animal sources, primarily genetically engineered swine, into humans to address shortages of human donor organs; core offerings encompass technologies to overcome immunological barriers, including genetic modifications to reduce immunogenicity, immunosuppressive therapies, organ preservation solutions, and preclinical xenografts such as porcine hearts, kidneys, livers, and skin grafts. The company holds a commercial license agreement with Massachusetts General Hospital to advance xenotransplantation applications for public use, targeting end-stage organ failure patients in the healthcare sector with emphasis on complex medical needs in transplantation and regenerative medicine. Founded in 2004 and headquartered in Brookline, Massachusetts, with historical addresses in Vancouver, Canada, Xeno Transplants conducts operations in the United States within the pharmaceuticals and biotechnology industry, trading as common stock on the OTC Pink marketplace. Recent major developments include sustained focus on therapeutic applications of genetically engineered porcine organs and cells as alternatives to limited human donors, with no reported funding rounds, acquisitions, partnerships, or new product launches in the last 1-2 years, reflecting a niche, speculative position in the emerging xenotransplantation field amid broader industry advancements by competitors.